Drugs / CL20-i4-EF1α-hγc-OPT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01512888 | Aug 2016 → Aug 2026 | combined immunodeficiency, X-linked | St. Jude Children's Research Hospital | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CL20-i4-EF1α-hγc-OPT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01512888 ↗ |
| Action | Restore | “This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells.” NCT01512888 ↗ |
| Target | IL2RG | “a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells” PMID 30995372 ↗ Apr 2019 |